

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

RPMI-8226/Dox40

RRID:CVCL_J431

Type: Cell Line

Proper Citation

RRID:CVCL_J431

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_J431

Proper Citation: RRID:CVCL_J431

Description: Cell line RPMI-8226/Dox40 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:2563664](#), [PMID:2569359](#), [PMID:10095106](#), [PMID:10825126](#), [PMID:11309308](#)

Comments: Characteristics: Produces IgG lambda (from parent cell line RPMI-8226)., Characteristics: Resistant to 40 x 10⁻⁸ M of doxorubicin (PubMed=2563664)., Population: African American.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RPMI-8226/Dox40

Synonyms: RPMI 8226/DOX40, RPMI-8226DOX40, 8226/DOX40, 8226/Dox40, 8226/Dox(40), 8226 Dox40, 8226Dox40, Dox40

Cross References: cancercellines:CVCL_J431, Wikidata:Q54951246

ID: CVCL_J431

Hierarchy: cvcl_0014

Record Creation Time: 20220427T221507+0000

Record Last Update: 20260905T182234+0000

Ratings and Alerts

No rating or validation information has been found for RPMI-8226/Dox40.

No alerts have been found for RPMI-8226/Dox40.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Research square.